Deven Choksey
We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.
Deven Choksey upgraded Alembic Pharmaceuticals Ltd. to Buy with a price target of 1132.0 on 05 Nov, 2025.
More from Alembic Pharmaceuticals Ltd.
Recommended